The Role of Osteopontin and Visfatin as Diagnostic Markers in Thyroid Disorders
DOI:
https://doi.org/10.46966/msjar.v6i1.256Keywords:
Thyroid disease, Osteopontin, Visfatin, Biomarkers, Endocrine disorders, Metabolic markers.Abstract
Background: Both Osteopontin and Visfatin remain underexplored in the context of thyroid disorders. Nonetheless, taking into account their association with inflammation and metabolic alterations, further investigation on OPN and Visfatin is necessary within the scope of thyroid disorders. Initial biomarker stage for disease progress can enhance diagnosis, monitoring, and checkup frequency. Biochemical changes in the endocrine system signal the presence of disturbances in the body systems. Evaluation of thyroid diseases and the biology of ossification is essential because they are prevalent pathologies in the population. Osteopontin plays an essential role in the development, growth and metabolic activities of cells resulting in bone tissue architecture. Functions of Visfatin in governing metabolic processes appear relatively novel. Objectives: This first study, we hope to make an attempt in examining the diagnostic value of serum OPN and Visfatin levels among thyroid disease patients. Moreover, identify differences between thyroid disease patients and matched healthy participants concerning serum levels of Osteopontin and Visfatin. Methods: The study conducted is a case-control study of 60 patients with thyroid disease and 60 healthy controls. Blood samples were collected, from which serum Osteopontin and Visfatin levels were quantified. Correlation between Visfatin, Osteopontin, age, and BMI, and other background variables were also conducted. Results: Osteopontin and Visfatin levels in patients with Thyroid disease and controls will be discussed. In patients with thyroid disease, Osteopontin levels were significantly lower (4.13 ± 1.40 μg/L) than in controls (6.20 ± 1.91 μg/L) (p = 0.001). Visfatin levels were significantly greater in the patients (3.49 ± 0.53 ng/mL) than in controls (1.8 ± 0.18 ng/mL) (p = 0.01). No significant correlation was observed between Osteopontin and age/BMI (p > 0.05). There was a weak correlation noted between Visfatin and BMI (p = 0.037). Conclusion: These results imply that Osteopontin and Visfatin might be considered potential markers for thyroid disease. The outlined results suggest biphasic changes in OPN and Visfatin as a part of a particular biochemical pattern associated with thyroid dysfunction, lower OPN and higher Visfatin possibly indicating inflammatory and metabolic derangement in thyroid disease.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Samar Hasan Shammar

This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.


















